Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

ESMO open·2025
Same author

Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2025
Same author

Diagnostic and prognostic yields of ambulatory blood pressure measurements in haemodialysis patients: a 6-year longitudinal study.

Acta cardiologica·2024
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

"Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies.

The journal of prevention of Alzheimer's disease·2024
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024

Related Experiment Video

Updated: Feb 16, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.9K

EU./U.S. CTAD Task Force on Alzheimer's Trial Populations.

B Vellas1, C Sampaio, R Bateman

  • 1Professor Bruno Vellas, MD, PhD, Hôpital Casselardit, Gerontopole, UMR INSERM1027, 170 Avenue Casselardit, 31059 Toulouse Cedex 03, France.

The Journal of Prevention of Alzheimer'S Disease
|December 20, 2017
PubMed
Summary

Selecting the right participants is crucial for Alzheimer's disease (AD) drug trials. Using advanced imaging like amyloid PET can improve trial accuracy by identifying patients with actual Alzheimer's pathology.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.9K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.8K

Related Experiment Videos

Last Updated: Feb 16, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

1.9K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.9K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.8K

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Drug Development

Background:

  • Alzheimer's disease (AD) trials often include patients without confirmed amyloid pathology.
  • Dementia stages may be too advanced for disease-modifying therapies to be effective.

Purpose of the Study:

  • To address challenges in screening and identifying participants for AD clinical trials.
  • To improve the selection of study populations for effective drug development in dementia.

Main Methods:

  • An international task force convened to discuss participant selection criteria.
  • Focus on the impact of screening decisions on Alzheimer's disease drug development.

Main Results:

  • Amyloid PET imaging reveals many participants in AD trials lack brain amyloidosis.
  • Current trial populations may not be optimally targeted for disease-modifying interventions.

Conclusions:

  • Accurate participant selection, guided by biomarkers like amyloid PET, is essential for successful AD therapeutics.
  • Optimizing trial populations is critical for advancing drug development for Alzheimer's disease and other dementias.